Osteopontin as a target for cancer therapy

被引:64
作者
Johnston, Nicholas I. F. [1 ]
Gunasekharan, Vignesh Kumar [1 ]
Ravindranath, Amod [1 ]
O'Connell, Ciara [2 ]
Johnston, Patrick G. [1 ]
El-Tanani, Mohamed K. [1 ]
机构
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland
[2] Queens Univ Belfast, Sch Med & Dent, Belfast BT9 7BL, Antrim, North Ireland
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷
关键词
osteopontin transformation metastasis cancer therapy; review;
D O I
10.2741/3009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Osteopontin (OPN) is a glycophosphoprotein cytokine that has multiple functions. OPN is expressed and secreted by various cells, and has a role in cell adhesion, chemotaxis, prevention of apoptosis, invasion, migration and anchorage-independent growth of tumor cells. Extensive research has demonstrated the pivotal participation of OPN in the regulation of cell signaling which controls neoplastic and malignant transformation. The elevated expression of OPN has been observed in a variety of cancers. OPN has been linked with tumor metastasis and signifies a poor prognosis for the patient. This review details the mechanisms by which OPN facilitates these pathological events. It will also show that gaining an understanding of the mechanism of OPN's action at a cellular level has led to the development of a number of therapeutic strategies against the cytokine. These include inhibiting its expression, antagonizing cell surface receptor activation and blocking downstream cell signaling pathways. In addition to the potential of these therapies, serum levels of OPN could be used as a diagnostic and prognostic marker. The authors propose that with further research and development, osteopontin directed treatment could greatly enhance outcomes for cancer patients.
引用
收藏
页码:4361 / 4372
页数:12
相关论文
共 109 条
[1]
Axis of evil: molecular mechanisms of cancer metastasis [J].
Bogenrieder, T ;
Herlyn, M .
ONCOGENE, 2003, 22 (42) :6524-6536
[2]
BOS JL, 1989, CANCER RES, V49, P4682
[3]
Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer [J].
Brakora, KA ;
Lee, H ;
Yusuf, R ;
Sullivan, L ;
Harris, A ;
Colella, T ;
Seiden, MV .
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) :361-365
[4]
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer [J].
Bramwell, Vivien H. C. ;
Doig, Gordon S. ;
Tuck, Alan B. ;
Wilson, Sylvia M. ;
Tonkin, Katia S. ;
Tomiak, Anna ;
Perera, Francisco ;
Vandenberg, Theodore A. ;
Chambers, Ann F. .
CLINICAL CANCER RESEARCH, 2006, 12 (11) :3337-3343
[5]
INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[6]
BROWN LF, 1994, AM J PATHOL, V145, P610
[7]
EXPRESSION AND DISTRIBUTION OF OSTEOPONTIN IN HUMAN TISSUES - WIDESPREAD ASSOCIATION WITH LUMINAL EPITHELIAL SURFACES [J].
BROWN, LF ;
BERSE, B ;
VANDEWATER, L ;
PAPADOPOULOSSERGIOU, A ;
PERRUZZI, CA ;
MANSEAU, EJ ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (10) :1169-1180
[8]
The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis [J].
Chakraborty, Goutam ;
Jain, Shalini ;
Behera, Reeti ;
Ahmed, Mansoor ;
Sharma, Priyanka ;
Kumar, Vinit ;
Kundu, Gopal C. .
CURRENT MOLECULAR MEDICINE, 2006, 6 (08) :819-830
[9]
CHAMBERS AF, 1992, ANTICANCER RES, V12, P43
[10]
CHAMBERS AF, 1993, CANCER RES, V53, P701